Literature DB >> 20231232

Lenient versus strict rate control in patients with atrial fibrillation.

Isabelle C Van Gelder1, Hessel F Groenveld, Harry J G M Crijns, Ype S Tuininga, Jan G P Tijssen, A Marco Alings, Hans L Hillege, Johanna A Bergsma-Kadijk, Jan H Cornel, Otto Kamp, Raymond Tukkie, Hans A Bosker, Dirk J Van Veldhuisen, Maarten P Van den Berg.   

Abstract

BACKGROUND: Rate control is often the therapy of choice for atrial fibrillation. Guidelines recommend strict rate control, but this is not based on clinical evidence. We hypothesized that lenient rate control is not inferior to strict rate control for preventing cardiovascular morbidity and mortality in patients with permanent atrial fibrillation.
METHODS: We randomly assigned 614 patients with permanent atrial fibrillation to undergo a lenient rate-control strategy (resting heart rate <110 beats per minute) or a strict rate-control strategy (resting heart rate <80 beats per minute and heart rate during moderate exercise <110 beats per minute). The primary outcome was a composite of death from cardiovascular causes, hospitalization for heart failure, and stroke, systemic embolism, bleeding, and life-threatening arrhythmic events. The duration of follow-up was at least 2 years, with a maximum of 3 years.
RESULTS: The estimated cumulative incidence of the primary outcome at 3 years was 12.9% in the lenient-control group and 14.9% in the strict-control group, with an absolute difference with respect to the lenient-control group of -2.0 percentage points (90% confidence interval, -7.6 to 3.5; P<0.001 for the prespecified noninferiority margin). The frequencies of the components of the primary outcome were similar in the two groups. More patients in the lenient-control group met the heart-rate target or targets (304 [97.7%], vs. 203 [67.0%] in the strict-control group; P<0.001) with fewer total visits (75 [median, 0], vs. 684 [median, 2]; P<0.001). The frequencies of symptoms and adverse events were similar in the two groups.
CONCLUSIONS: In patients with permanent atrial fibrillation, lenient rate control is as effective as strict rate control and is easier to achieve. (ClinicalTrials.gov number, NCT00392613.) 2010 Massachusetts Medical Society

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20231232     DOI: 10.1056/NEJMoa1001337

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  187 in total

1.  MEDEX South Carolina: a progress report.

Authors:  K J Buhmeyer; A R Hutson
Journal:  J S C Med Assoc       Date:  1975-11

2.  Fast atrial fibrillation and caecal volvulus--a case report and evidence based management.

Authors:  Alexander Liu; Edward Nicol
Journal:  BMJ Case Rep       Date:  2011-12-20

Review 3.  Atrial fibrillation in 2010: advances in treatment and management.

Authors:  Stuart J Connolly
Journal:  Nat Rev Cardiol       Date:  2011-02       Impact factor: 32.419

4.  Rate versus rhythm in atrial fibrillation: and how slow do you go?

Authors:  G Michael Allan; Christina Korownyk; Michael R Kolber
Journal:  Can Fam Physician       Date:  2011-12       Impact factor: 3.275

Review 5.  Symptoms and functional status of patients with atrial fibrillation: state of the art and future research opportunities.

Authors:  Michiel Rienstra; Steven A Lubitz; Saagar Mahida; Jared W Magnani; João D Fontes; Moritz F Sinner; Isabelle C Van Gelder; Patrick T Ellinor; Emelia J Benjamin
Journal:  Circulation       Date:  2012-06-12       Impact factor: 29.690

6.  PURLS: A-fib and rate control: don't go too low.

Authors:  Kristen Deane; Kohar Jones; James J Stevermer
Journal:  J Fam Pract       Date:  2010-08       Impact factor: 0.493

7.  Atrial fibrillation and obstructive lung disease: Don't fear the β-blocker.

Authors:  Zak Loring; Jonathan P Piccini
Journal:  Heart Rhythm       Date:  2018-07-19       Impact factor: 6.343

8.  Heart rate and outcome in heart failure with reduced ejection fraction: Differences between atrial fibrillation and sinus rhythm-A CIBIS II analysis.

Authors:  Bart A Mulder; Kevin Damman; Dirk J Van Veldhuisen; Isabelle C Van Gelder; Michiel Rienstra
Journal:  Clin Cardiol       Date:  2017-05-17       Impact factor: 2.882

Review 9.  [Current treatment of tachycardia].

Authors:  J Tebbenjohanns; K Rühmkorf
Journal:  Internist (Berl)       Date:  2013-12       Impact factor: 0.743

10.  Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation.

Authors:  David P Kao; Gordon Davis; Ryan Aleong; Christopher M O'Connor; Mona Fiuzat; Peter E Carson; Inder S Anand; Jonathan F Plehn; Stephen S Gottlieb; Marc A Silver; JoAnn Lindenfeld; Alan B Miller; Michel White; Guinevere A Murphy; Will Sauer; Michael R Bristow
Journal:  Eur J Heart Fail       Date:  2012-12-07       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.